

Dear Lori,

Thank you for your e-mail dated 25 May 2010 and addressed to my colleague [REDACTED], inviting us to comment on the NICE ACD for the first line treatment of multiple myeloma.

Celgene UK is of the view that all relevant evidence has been taken into account and the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence.

Whilst we broadly agree with the provisional recommendations, we'd like to reiterate that any final NICE recommendation regarding the first line treatment of multiple myeloma should leave enough room for clinicians and patients to use the treatment which suits them best.

Kind Regards

[REDACTED]

[REDACTED]

Celgene Ltd (UK & Ireland)

Morgan House | Madeira Walk

Windsor | BERKSHIRE | SL4 1EP

Tel: +44 1753 498 631

Mob: +44 7825 007 603

Email: sdhanasiri@celgene.com